|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2000-12-1
|
|
pubmed:abstractText |
Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-beta (IFN-beta) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-beta1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-beta treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ 'memory' T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD27,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD29,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD45,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD58,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD8,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alpha4,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alpha4beta1,
http://linkedlifedata.com/resource/pubmed/chemical/Integrins,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphocyte Function-Associated...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Lymphocyte Homing
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0165-5728
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
111
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
186-94
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11063837-Adjuvants, Immunologic,
pubmed-meshheading:11063837-Antigens, CD,
pubmed-meshheading:11063837-Antigens, CD27,
pubmed-meshheading:11063837-Antigens, CD29,
pubmed-meshheading:11063837-Antigens, CD4,
pubmed-meshheading:11063837-Antigens, CD45,
pubmed-meshheading:11063837-Antigens, CD58,
pubmed-meshheading:11063837-Antigens, CD8,
pubmed-meshheading:11063837-Biological Markers,
pubmed-meshheading:11063837-Down-Regulation,
pubmed-meshheading:11063837-Female,
pubmed-meshheading:11063837-Flow Cytometry,
pubmed-meshheading:11063837-HLA-DR Antigens,
pubmed-meshheading:11063837-Humans,
pubmed-meshheading:11063837-Immunologic Memory,
pubmed-meshheading:11063837-Integrin alpha4,
pubmed-meshheading:11063837-Integrin alpha4beta1,
pubmed-meshheading:11063837-Integrins,
pubmed-meshheading:11063837-Intercellular Adhesion Molecule-1,
pubmed-meshheading:11063837-Interferon-beta,
pubmed-meshheading:11063837-Lymphocyte Function-Associated Antigen-1,
pubmed-meshheading:11063837-Magnetic Resonance Imaging,
pubmed-meshheading:11063837-Male,
pubmed-meshheading:11063837-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:11063837-Receptors, Lymphocyte Homing,
pubmed-meshheading:11063837-T-Lymphocytes
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.
|
|
pubmed:affiliation |
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive MSC1400, 20892-1400, Bethesda, MD, USA. pmuraro@umich.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
